Navigation Links
Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
Date:10/16/2007

of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit http://www.mylan.com

This press release includes statements that constitute "forward-looking statements," including with regard to Perforomist and research results. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the risk that the product may not ultimately prove to be as successful as anticipated; the impact of the competitive COPD environment; and the other risks detailed in the Company's Form 10-Q for the quarter ended June 30, 2007 and its other periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media contacts: Dey, L.P. Media Line

1-800-755-5560 ext. 8363

or

Harriet Ullman

Feinstein Kean Healthcare

617-761-6776

hullman@fkhealth.com


'/>"/>
SOURCE Dey, L.P.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
3. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
4. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
5. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
6. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
7. Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
8. Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting
9. Data supporting three Antisoma programmes presented at AACR
10. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
11. Genetic Analysis Systems Enter the Clinical Mainstream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...rmaceuticals (SPI) has filed,an Investigational Ne...esting of a proprietary formulation of ebselen for...ss or ototoxicity. The oral capsule,containing ebs...ung cancer,and head and neck cancer patients recei...econd development program for SPI to enter clinica...
(Date:7/23/2008)...ma Inc., a company developing,breakthrough molecul...aphy,(PET) market, announced positive Phase I resu...r for myocardial perfusion imaging. BFPET is,Fluor...e Phase I clinical,development., BFPET is a PET i... the,heart (myocardial perfusion). Myocardial perf...
(Date:7/23/2008)...ode BioPharmaceutics, Inc.,an emerging biopharmac...results demonstrating the utility of their lead dr...hronic blood disorder paroxysmal nocturnal,hemoglo...ted at the XXII,International Complement Workshop ...nly treatment currently available for PNH patients...
(Date:7/23/2008)...Protein Therapeutics that Modulate Alter...ass., July 23 /- Taligen Therapeutics... growth plan with the,appointment of Abbie Celnike...lishment of its headquarters in Cambridge, Mass. D...under of the company who remains president., Unde...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 1Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 5Threepeat for HealthPus 21 4676 1NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 1NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 2NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 3Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 1Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 2Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 3Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 4Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 5
...2007 - Elixir,Pharmaceuticals, Inc., announced tod...he ability of Glufast(R) (mitiglinide calcium,hydr...ormin, to,manage glucose surges before and after m... for the American Diabetes,Association 67th Annual... is an insulin secretagogue that lowers postprandi...
...- CytRx Corporation,(NASDAQ:CYTR), a biopharmaceut...cialization of human therapeutics, today,reported ...y,announced double-blind, placebo-controlled, risi...ers with its drug candidate,arimoclomol. CytRx bel...se of arimoclomol in future clinical trials, inclu...
Other Medicine Technology:Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 2CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 3CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 4CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 5
(Date:7/25/2008)...S, July 25 /PRNewswire/ -- BeaconEquity.com announ...ing news today., Investors can view all of the da...aconEquity.com/m , Today,s Trade Alerts include: ...Brook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaM...R ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis I...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins ... -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ...d today that its subsidiary has commenced commerci...ules USP product in the 40mg,strength from its Dav...,with the launch, Watson has 180 days of marketing...
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...can be toughest for those trying to drop pounds, s...y News) -- Anyone who has avoided Monday morning w...e not a dieter,s friend. , Now, researchers hav...t weekends being their undoing: Most people do eat...lose weight. , "Weekend indulgences can wreak h...
Breaking Medicine News(10 mins):Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...pective study conducted by researchers from the Ge...rfs in ancient Egypt had received their much-deser...emains and other art forms demonstrated that dwarf...ical deformity. Infact, ancient Egyptians even wo...
...an woman was ecstatic that she and her daughter tr...mas in an intensive care unit // . Mariam Ameh’s ...ell after journeying to Cleveland's Rainbow Babies...e doctors removed a brain tumor the size of a grap...
...r Lloyd Johnston of the University of Michigan in ...e was a decrease in smoking in these students but ...ous painkillers // . The researchers found that al...g drugs. The increase in use of painkillers may be...
...abia is gearing up to face around 2.5 million Hajj...reening when they enter Saudi Arabia to all the Ha...ion//. World wide the threat of pandemic bird flu ...ns and spread of the virus is high in mass gatheri...
Other Medicine News:Health News:Respecting Dwarfs- A Lesson To Be Learnt From Ancient Egyptians 2Health News:Nigerian girl recovering well after removal of brain tumor 2
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: